Since Prior Flu Exposure Dictates Your Future Immune Response, New Vaccine Regiments Can Be Rationally Developed, Researchers Say
A team of scientists, led by researchers at The Wistar Institute, has determined that it might be possible to stimulate the immune system against multiple strains of influenza virus by sequentially vaccinating individuals with distinct influenza strains isolated over the last century.
Their results also suggest that world health experts might need to re-evaluate standard tests used for surveillance of novel influenza strains. Their findings are published in the Journal of Experimental Medicine.
According to the Wistar researchers, their analysis could lead to an alternative approach to creating a “universal” flu vaccine—a vaccine that would provide resistance to seasonal and pandemic influenza strains over many years, negating the need for an annual flu shot.
“Influenza vaccines are very safe and provide good protection. However, we need to continuously update seasonal flu vaccines because influenza viral proteins change over time,” said Scott Hensley, Ph.D., an assistant professor at The Wistar Institute and corresponding author on the study. “Since influenza viruses are constantly changing, we all have unique pre-exposure histories that depend on when we were born and the specific types of viruses that circulated during our childhood.”
Vaccines work by stimulating the immune system to produce antibody proteins against particles (called antigens) from an infectious agent, such as bacteria or a virus. The immune system saves the cells that produce effective antibodies, which then provide immunity against future attacks by the same or similar infectious agents. Despite the availability of a vaccine, seasonal influenza typically kills 36,000 Americans, alone, and nearly a half million individuals around the world, in total.
Most current efforts to create universal vaccines hinge on the idea of generating antibodies against a portion of the virus that is relatively unchanged year-to-year.
“Our studies demonstrate that individuals that are infected sequentially with dramatically different influenza strains mount antibody responses against a conserved region of influenza virus,” Hensley said. “Since we now know that pre-exposure events can influence vaccine responsiveness in a predictable way, we can begin to design vaccine regiments that preferentially elicit antibody responses against conserved regions of influenza virus.”
The researchers began their current work by studying human antibody responses against the 2009 pandemic H1N1 virus. The 2009 strain is antigenically distinct from recently circulating seasonal H1N1 strains, and a distant relative of the virus that caused the devastating “Spanish Flu” of the early 20th century. The most effective antibodies are those that bind to a particular portion (or “epitope”) of hemagglutinin (HA), a protein produced by the influenza virus.
According to Hensley, however, their chief insight occurred when his team hit the “sort” button on a spreadsheet document, thereby arranging all samples by age of the donor. Different aged people, they found, mount vastly different antibody responses to pandemic H1N1, depending on whether or not they were exposed to a seasonal H1N1 years earlier. “We can now accurately predict how individuals will respond to the pandemic H1N1 strain based on the year that they were born,” Hensley said.
Their investigation also suggests that ferrets with no prior influenza exposure might not be the most reliable predictor of human immune responses. Anti-sera—or blood containing antibodies–created in these “naïve” ferrets are commonly used for influenza surveillance. The researchers found that naïve ferrets mount a response to an epitope in a decidedly different portion of HA than do most humans, but subsequently infecting these ferrets with other historical influenza strains can shift the antibody response toward the epitope that human antibodies recognize. This shift might also be replicable in humans through multiple infections or vaccinations, the researchers believe.
According to Hensley, one strategy would be to sequentially vaccinate children with antigenically distinct viral strains. “Babies are born with an immunological blank slate,” Hensley said. “We may be able to strategically vaccinate our children with antigenically diverse influenza strains to elicit antibodies against conserved viral epitopes.”
The Latest Bing News on:
Universal Influenza Vaccine
- For Insight On New Covid-19 Variants, Look To Natural History Of Coronaviruseson January 21, 2021 at 7:45 am
Though the human coronavirus 229E isn’t nearly as hot a topic as SARS-CoV-2 these days, it is one of several coronaviruses that have been causing us colds for more than half a century. It also has ...
- ImmunityBio Announces Phase I Trial of COVID-19 Vaccine Candidate in South Africa as New Variants of SARS-CoV-2 Spreadon January 19, 2021 at 10:58 pm
ImmunityBio, Inc., a privately-held immunotherapy company, today announced it has received authorization from the South Africa Health Products ...
- LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccineon January 19, 2021 at 8:56 am
LLNL researchers Nick Fischer and Amy Rasley are characterizing nanolipoprotein particle vaccine formulations using a dynamic ...
- Near-universal adoption of masks along with public health measures could eliminate disease spreadon January 18, 2021 at 3:42 pm
Research published this month in the Proceedings of the National Academy of Sciences found that near-universal adoption of nonmedical masks in public, combined with complementary public health ...
- Model analyzes how viruses escape the immune systemon January 17, 2021 at 7:56 am
One reason it’s so difficult to produce effective vaccines against some viruses, including influenza and HIV, is that these viruses mutate very rapidly.
- Algorithms Designed to Study Language Can Predict Immune “Escape” Mutations for HIV, Influenza, and SARS-CoV-2on January 15, 2021 at 5:00 am
MIT researchers used machine learning algorithms to identify protein sequences that might represent better targets for vaccines.
- Behind India’s coronavirus vaccine plan is an army of poorly paid female health workerson January 14, 2021 at 9:39 pm
Asha workers, along with the volunteer Anganwadi workers, and the more qualified auxiliary nurse midwives, form the backbone of community healthcare in India.
- Researchers close in on 'universal' flu vaccine as COVID-19 fight takes priorityon January 8, 2021 at 12:22 pm
8 (UPI) --Researchers believe they are one step closer to a "universal" flu ... allergic reaction to COVID-19 vaccine 'exceedingly rare' Using mice infected with influenza A, he and his colleagues ...
- Turned away and told to wait: My frustrating experience navigating the COVID-19 pandemic without an Ontario health cardon January 1, 2021 at 4:00 pm
Ontario’s Ministry of Health’s website states that under its Universal Influenza Immunization ... eligible to receive publicly funded influenza vaccine.” Pharmacies need only submit a ...
- Colorado bioscience companies ramp up vaccine development in 2021on December 31, 2020 at 11:05 am
is developing a nasal spray that actually would be a universal flu vaccine combined with a vaccine for Covid-19. “There’s a real potential for crisis if there’s a major influenza season that ...
The Latest Google Headlines on:
Universal Influenza Vaccine
The Latest Bing News on:
- More than 200 COVID-19 vaccines are still in development, with some now focusing on mutant strains and older peopleon January 23, 2021 at 11:06 am
Experts say the best COVID-19 vaccines may not actually exist yet, with researchers set to learn from the first rollouts and evolve the science to target new mutant strains and specific populations ...
- COVID-19 vaccine ingredients can trigger allergic reactions, but officials say it's rareon January 23, 2021 at 5:42 am
It's unclear which COVID-19 vaccine ingredients may trigger rare severe allergic reactions, but scientists' number one suspect is a common substance.
- Nearly 2,000 vaccine doses spoiled at Boston hospitalon January 23, 2021 at 5:31 am
Staff at the Jamaica Plain VA Medical Center discovered on Tuesday that a freezer had failed, compromising 1,900 doses of the Moderna COVID-19 vaccine.
- Why Moderna's COVID Vaccine Is Just the Tip of the Icebergon January 23, 2021 at 3:05 am
Corinne Cardina and Fool.com writer Keith Speights discuss why Moderna's COVID-19 vaccine is just the tip of the iceberg for the company. Corinne Cardina: Absolutely. Let's look at Moderna beyond its ...
- Research on COVID-19 Vaccination Technology Could Lead to HIV, Cancer Vaccineson January 22, 2021 at 7:24 pm
New vaccines for HIV and seasonal flu are currently under development using the mRNA technique, along with vaccine therapies that could provide new treatments for cancer and other ailments.
- Pfizer says its Covid vaccine trial for kids ages 12 to 15 is fully enrolledon January 22, 2021 at 2:10 pm
Pfizer's Covid-19 vaccine is authorized for people age 16 and older. The company's trial in kids 12-15 is now fully enrolled, a key step for use in kids.
- Viral Video Makes False and Unsupported Claims About Vaccineson January 22, 2021 at 11:20 am
A viral video makes a series of inaccurate and unfounded arguments for why people should not receive any vaccines, including those for COVID-19.
- High-dose and standard flu vaccines equally safe in older adults: studyon January 21, 2021 at 9:00 pm
A post-vaccination study has found that high-dose and standard adjuvanted influenza vaccines are equally safe in older adults and have virtually the same short-term effects on quality of life.
- Either trivalent flu vaccine safe for use in seniorson January 21, 2021 at 6:42 am
Either the trivalent adjuvanted inactivated influenza vaccine (aIIV3) or the trivalent high-dose inactivated influenza vaccine (HD-IIV3) is safe to use in older adults, according to a study published ...
- Influenza Vaccines Market 2020 Driving Factors, Industry Growth, Key Vendors and Forecasts to 2025on January 20, 2021 at 8:49 am
Selbyville, Delaware, The next five years the Influenza Vaccines market will register a 4.9% CAGR in terms of revenue, the global market size will reach $ 3752.1 million by 2025, from $ 3099.1 million ...